Kopran Limited submitted its financial results for the quarter and year ended March 31, 2026, to the NSE on May 19, 2026, following a board meeting held the same day. The Mumbai-based pharmaceutical company has maintained its final dividend at ₹3.00 per equity share for the fourth straight fiscal year, reflecting consistent but unchanged shareholder returns against a backdrop of elevated valuations.

Dividend Details and Yield

The board recommended a final dividend of ₹3.00 per equity share on shares with ISIN INE082A01010. At the current market price of ₹173.88, this translates to a dividend yield of approximately 1.72%. The payout has remained flat since FY2022, when the company first declared ₹3.00 per share on May 27, 2022. Subsequent declarations on May 25, 2023, May 16, 2024, and May 15, 2025 each carried the identical ₹3.00 figure, establishing a pattern of consistency rather than growth in dividend distribution.

Dividend Trend Analysis

While the company has demonstrated reliability in dividend payments, the absence of any increase over four years means the effective yield has fluctuated purely as a function of share price movement rather than any upward revision in payout policy.

Valuation and Sector Context

Kopran's current price-to-earnings ratio stands at 48.22x, which is identical to the sector PE of 48.22x, placing the stock precisely in line with its pharmaceutical peers. This alignment suggests the market is pricing Kopran at a sector-average multiple, leaving limited valuation premium or discount relative to the broader industry group.

Market Performance and Price Range

The stock closed at ₹173.88 on May 19, 2026, gaining ₹8.69 or 5.26% on the day, likely reflecting market reaction to the results announcement. However, the current price remains well below its 52-week high of ₹212.58 reached on June 12, 2025, and is 62.5% above its 52-week low of ₹107.00 touched on March 30, 2026. The stock has recovered meaningfully from its annual trough but has not reclaimed its peak levels.

Trading Activity and Delivery Data

Trading volumes on the results day were notably elevated at 40,68,849 shares. The delivery percentage came in at 29.37%, which indicates that roughly seven out of ten shares traded were intraday in nature. A delivery percentage below 30% in a high-volume session can signal speculative or short-term positioning rather than sustained institutional accumulation. Daily volatility is recorded at 3.02%, consistent with the stock's recent price swings.

Company Background

Kopran Limited is an integrated pharmaceutical manufacturer with operations spanning bulk drugs and formulations. The company is listed on the NSE under the symbol KOPRAN and carries a market capitalisation of ₹839.24 Cr as of the latest trading session, placing it in the small-cap segment of Indian listed pharma.

Investors tracking Kopran will note that while dividend consistency is present, the flat payout trajectory over four years and a delivery percentage below 30% on a high-volume day are data points warranting close monitoring as the company's FY26 earnings details become fully available for analysis.